Impairment of TGF-β signaling in T cells increases susceptibility to experimental autoimmune hepatitis in mice

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 284, Issue 3 47-3, 2003, Pages

  Schramm, Christoph ^a   Protschka, Martina ^a   Köhler, Heinz H ^a   Podlech, Jürgen ^a   Reddehase, Matthias J ^a   Schirmacher, Peter ^b   Galle, Peter R ^a   Lohse, Ansgar W ^a   Blessing, Manfred ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Dominant negative transforming growth factor type II receptor; Transgenic mice

Indexed keywords

CD2 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA2 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE HEPATITIS; DISEASE PREDISPOSITION; HISTOPATHOLOGY; IMMUNE RESPONSE; LIVER NECROSIS; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATOR GENE; T LYMPHOCYTE; TRANSGENIC MOUSE;

EID: 0037370898     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00286.2002     Document Type: Article

References (56)

1. Ahuja SS, Paliogianni F, Yamada H, Balow JE, and Boumpas DT. Effect of transforming growth factor-beta on early and late activation events in human T cells. J Immunol 150: 3109-3118, 1993.
2. Attisano L, Carcamo J, Ventura F, Weis FM, Massague J, and Wrana JL. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 75: 671-680, 1993.
3. Attisano L, Wrana JL, Lopez-Casillas F, and Massague J. TGF-beta receptors and actions. Biochim Biophys Acta 1222: 71-80, 1994.
4. Bayer EM, Herr W, Kanzler S, Waldmann C, Meyer zum Büschenfelde KH, Dienes HP, and Lohse AW. Transforming growth factor-beta1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity. J Hepatol 28: 803-811, 1998.
5. Bedossa P and Paradis V. Transforming growth factor-beta (TGF-beta): a key-role in liver fibrogenesis. J Hepatol 22: 37-42, 1995.
6. Bolland S and Ravetch JV. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 13: 277-285, 2000.
7. Brand T, MacLellan WR, and Schneider MD. A dominant-negative receptor for type beta transforming growth factors created by deletion of the kinase domain. J Biol Chem 268: 11500-11503, 1993.
8. Cazac BB and Roes J. TGF-beta receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 13: 443-451, 2000.
9. Church GM and Gilbert W. Genomic sequencing. Proc Natl Acad Sci USA 81: 1991-1995, 1984.
10. Czaja AJ, Ludwig J, Baggenstoss AH, and Wolf A. Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med 304: 5-9, 1981.
11. Czaja AJ, Manns MP, McFarlane IG, and Hoofnagle JH. Autoimmune hepatitis: the investigational and clinical challenges. Hepatology 31: 1194-1200, 2000.
12. Derynck R, Zhang Y, and Feng XH. Smads: transcriptional activators of TGF-beta responses. Cell 95: 737-740, 1998.
13. Diebold RJ, Eis MJ, Yin M, Ormsby I, Boivin GP, Darrow BJ, Saffitz JE, and Doetschman T. Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated. Proc Natl Acad Sci USA 92: 12215-12219, 1995.
14. Ebner R, Chen RH, Lawler S, Zioncheck T, and Derynck R. Determination of type I receptor specificity by the type II receptors for TGF-beta or activin. Science 262: 900-902, 1993.
15. Espevik T, Waage A, Faxvaag A, and Shalaby MR. Regulation of interleukin-2 and interleukin-6 production from T-cells: involvement of interleukin-1 beta and transforming growth factor-beta. Cell Immunol 126: 47-56, 1990.
16. Fargeas C, Wu CY, Nakajima T, Coxm D, Nutman T, and Delespesse G. Differential effect of transforming growth factor beta on the synthesis of Th1- and Th2-like lymphokines by human T lymphocytes. Eur J Immunol 22: 2173-2176, 1992.
17. Geiser AG, Letterio JJ, Kulkarni AB, Karlsson S, Roberts AB, and Sporn MB. Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatability genes in the postnatal mouse: aberrant histocompatability antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype. Proc Natl Acad Sci USA 90: 9944-9948, 1993.
18. Gorelik L, Fields PE, and Flavell RA. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol 165: 4773-4777, 2000.
19. Gorelik L and Flavell RA. Abrogation of TGF beta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12: 171-181, 2000.
20. Gorham JD, Lin JT, Sung JL, Rudner LA, and French MA. Genetic regulation of autoimmune disease: BALB/c background TGF-beta1-deficient mice develop necroinflammatory IFN-gamma-dependent hepatitis. J Immunol 166: 6413-6422, 2001.
21. Heath VL, Murphy EE, Crain C, Tomlinson MG, and O'Garra A. TGF-beta1 down-regulates Th2 development and results in decreased IL-4-induced STAT6 activation and GATA-3 expression. Eur J Immunol 30: 2639-2649, 2000.
22. Hogan BLM, Costatini F, and Lacy E. Manipulating the Mouse Embryo. A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1986.
23. Hussain MJ, Mustafa A, Gallati H, Mowat AP, Mieli-Vergani G, and Vergani D. Cellular expression of tumour necrosis factor-alpha and interferon-gamma in the liver biopsies of children with chronic liver disease. J Hepatol 21: 816-821, 1994.
24. Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, Rose-John S, Meyer zum Büschenfelde KH, and Blessing M. TGF-β1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol Gastrointest Liver Physiol 276: G1059-G1068, 1999.
25. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, and Fauci AS. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 163: 1037-1050, 1986.
26. Kim PH and Kagnoff MF. Transforming growth factor-beta 1 is a costimulator for IgA production. J Immunol 144: 3411-3416, 1990.
27. Kohda H, Sekiya C, Kanai M, Yoshida Y, Uede T, Kikuchi K, and Namiki M. Flow cytometric and functional analysis of mononuclear cells infiltrating the liver in experimental autoimmune hepatitis. Clin Exp Immunol 82: 473-478, 1990.
28. Krawitt EL. Autoimmune hepatitis. N Engl J Med 334: 897-903, 1996.
29. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, and Karlsson S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90: 770-774, 1993.
30. Kulkarni AB, Ward JM, Yaswen L, Mackall CL, Bauer SR, Huh CG, Gress RE, and Karlsson S. Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders. Am J Pathol 146: 264-275, 1995.
31. Kusters S, Gantner F, Kunstle G, and Tiegs G. Interferon-gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 111: 462-471, 1996.
32. Lang G, Wotton D, Owen MJ, Sewell WA, Brown MH, Mason DY, Crumpton MJ, and Kioussis D. The structure of the human CD2 gene and its expression in transgenic mice. EMBO J 7: 1675-1682, 1988.
33. Letterio JJ, Geiser AG, Kulkarni AB, Dang H, Kong L, Nakabayashi T, Mackall CL, Gress RE, and Roberts AB. Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression. J Clin Invest 98: 2109-2119, 1996.
34. Letterio JJ and Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 16: 137-161, 1998.
35. Lohse AW, Brunner S, Kyriatsoulis A, Manns M, and Meyer zum Büschenfelde KH. Autoantibodies in experimental autoimmune hepatitis. J Hepatol 14: 48-53, 1992.
36. Lohse AW, Dienes HP, and Meyer zum Büschenfelde KH. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression. Hepatology 27: 1536-1543, 1998.
37. Lohse AW, Kogel M, and Meyer zum Büschenfelde KH. Evidence for spontaneous immunosuppression in autoimmune hepatitis. Hepatology 22: 381-388, 1995.
38. Lohse AW, Manns M, Dienes HP, Meyer zum Büschenfelde KH, and Cohen IR. Experimental autoimmune hepatitis: disease induction, time course and T-cell reactivity. Hepatology 11: 24-30, 1990.
39. Lohse AW and Meyer zum Büschenfelde KH. Experimental hepatitis. In: Autoimmune Disease Models, edited by Cohen IR and Miller A. San Diego: Academic, 1994, p. 191-200.
40. Lucas PJ, Kim SJ, Melby SJ, and Gress RE. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor. J Exp Med 191: 1187-1196, 2000.
41. Miyazono K, Ten Dijke P, Ichijo H, and Heldin CH. Receptors for transforming growth factor-beta. Adv Immunol 55: 181-220, 1994.
42. Mule JJ, Schwarz SL, Roberts AB, Sporn MB, and Rosenberg SA. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 26: 95-100, 1988.
43. Nakao A, Miike S, Hatano M, Okumura K, Tokuhisa T, Ra C, and Iwamoto I. Blockade of transforming growth factor beta/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J Exp Med 192: 151-158, 2000.
44. Ogawa M, Mori Y, Mori T, Ueda S, Yoshida H, Kato I, Iesato K, Wakashin Y, Azemoto R, Wakashin M, Okuda K, and Ohto M. Adoptive transfer of experimental autoimmune hepatitis in mice - cellular interaction between donor and recipient mice. Clin Exp Immunol 73: 276-282, 1988.
45. Ohta A, Sekimoto M, Sato M, Koda T, Nishimura S, Iwakura Y, Sekikawa K, and Nishimura T. Indispensable role for TNF-alpha and IFN-gamma at the effector phase of liver injury mediated by Th1 cells specific to hepatitis B virus surface antigen. J Immunol 165: 956-961, 2000.
46. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, and Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253-261, 1993.
47. Sadlack B, Lohler J, Schorle H, Klebb G, Haber H, Sickel E, Noelle RJ, and Horak I. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 25: 3053-3059, 1995.
48. Smyth MJ, Strobl SL, Young HA, Ortaldo JR, and Ochoa AC. Regulation of lymphokine-activated killer activity and poreforming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta. J Immunol 146: 3289-3297, 1991.
49. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, and Calvin D. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359: 693-699, 1992.
50. Takenoshita S, Hagiwara K, Nagashima M, Gemma A, Bennett WP, and Harris CC. The genomic structure of the gene encoding the human transforming growth factor beta type II receptor (TGF-beta RII). Genomics 36: 341-344, 1996.
51. Toyonaga T, Hino O, Sugai S, Wakasugi S, Abe K, Shichiri M, and Yamamura K. Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver. Proc Natl Acad Sci USA 91: 614-618, 1994.
52. Tsunematsu S, Saito H, Tada S, Ebinuma H, Tsuchiya M, Kumagai N, Morizane T, Nomura T, and Ishii H. Susceptibility of experimental autoimmune hepatitis in transgenic mice overexpressing the c-H-ras gene. J Gastroenterol Hepatol 12: 319-324, 1997.
53. Van Ginkel FW, Wahl SM, Kearney JF, Kweon MN, Fujihashi K, Burrows PD, Kiyono H, and McGhee JR. Partial IgA-deficiency with increased Th2-type cytokines in TGF-beta 1 knockout mice. J Immunol 163: 1951-1957, 1999.
54. Wrana JL, Attisano L, Wieser R, Ventura F, and Massague J. Mechanism of activation of the TGF-beta receptor. Nature 370: 341-347, 1994.
55. Yaswen L, Kulkarni AB, Fredrickson T, Mittleman B, Schiffman R, Payne S, Longenecker G, Mozes E, and Karlsson S. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood 87: 1458-1465, 1996.
56. Zhumabekov T, Corbella P, Tolaini M, and Kioussis D. Improved version of a human CD2 minigene based vector for T cell-specific expression in transgenic mice. J Immunol Methods 185: 133-140, 1995.